Celldex’s Phase II trial set three doses of barzolvolimab against placebo in 208 patients with chronic spontaneous urticaria (CSU) who were symptomatic despite antihistamine treatment, including some who were refractory to biologics such as Novartis and Genentech’s Xolair. There are currently no approved treatments for patients whose disease is not controlled by Xolair.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.